GYNECOLOGIC TUMOR-MARKERS
GYNECOLOGIC TUMOR-MARKERS
复制标题
DOI：
10.1002/ssu.2980060604
复制
发表时间：
1990-01-01
期刊：
影响因子：
--
通讯作者：
BAST, RC
中科院分区：
文献类型：
--
作者：
OLT, GJ;BERCHUCK, A;BAST, RC
单克隆技术的出现增加了抗体依赖性肿瘤标志物检测在妇科肿瘤学中的潜在效用。针对肿瘤相关抗原上新表位的几种纯单克隆抗体的无限量可用性允许开发高灵敏度的血清标志物测定法。对人绒毛膜促性腺激素（hCG）、NB/70 K和TA-4的传统测定方法进行了改进。CA 125提供了一个有用的第一代标记物，用于监测卵巢癌和盆腔肿块患者的分诊，尽管灵敏度和特异性有限。在接下来的十年中，挑战是确定新的标志物，以补充CA 125在监测卵巢癌和促进筛查隐匿性早期疾病。可能需要涉及多种标记物和模式的策略。通过对妇科肿瘤生物学的基础知识，包括生长因子及其受体的表达，可能会出现一些标志物。最后，单克隆抗体在免疫组织化学和放射性核素显像中的应用也可能为单克隆抗体在妇科肿瘤学中的诊断应用提供新的领域。
The advent of monoclonal technology has increased the potential utility of antibody‐dependent tumor marker assays in gynecologic oncology. The availability of unlimited quantities of several pure monoclonal antibodies directed against novel epitopes on tumor‐associated antigens has permitted development of highly sensitive assays for serum markers. Traditional assays for human chorionic gonadotropin (hCG), NB/70K and TA‐4 have been improved. CA 125 has provided a useful first‐generation marker for monitoring ovarian cancer and triaging patients with pelvic masses, despite limitations in sensitivity and specificity. In the next decade, the challenge is to identify new markers that will complement CA 125 in monitoring ovarian cancer and facilitate screening for occult early‐stage disease. Strategies involving multiple markers and modalities may be required. Some markers may emerge through a more fundamental knowledge of the biology of gynecologic neoplasms, including the expression of growth factors and their receptors. Finally, the application of monoclonal antibodies to immunohistochemistry and radionuclide imaging also may provide new areas of diagnostic application for monoclonal antibodies in gynecologic oncology.